Scientists develop DNA-delivered immunotherapy that targets ovarian cancer more effectively. Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies. It's a major development for this type of immunotherapy, which has been used successfully against blood cancers but has so far been less effective in solid tumors.
- Ponto de atenção: scientists.
- Ponto de atenção: develop.
- Ponto de atenção: delivered.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
